{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:32:50Z","timestamp":1791073970522,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the potential efficacy of ubrogepant for acute treatment of migraine based on historical experience with triptans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although triptans have improved migraine treatment, their efficacy and tolerability may limit their utility in some individuals. Ubrogepant is a small\u2010molecule, oral calcitonin gene\u2013related peptide receptor antagonist approved by the Food and Drug Administration for acute treatment of migraine in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis of pooled data from the pivotal trials ACHIEVE I and II, identically designed, randomized, double\u2010blind, phase 3, single\u2010attack trials of ubrogepant in adults with a history of migraine with\/without aura, examined the efficacy and tolerability of ubrogepant 50\u00a0mg versus placebo based on participants\u2019 historical experience with triptans: triptan responder, triptan\u2010insufficient responder, and triptan na\u00efve. Co\u2010primary efficacy endpoints were pain freedom and absence of most bothersome migraine\u2010associated symptom (MBS) 2\u00a0h post initial dose. Adverse events (AEs) within historical triptan experience subgroups were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the pooled analysis population (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a01799), 682 (placebo,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0350; ubrogepant 50\u00a0mg,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0332), 451 (placebo,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0223; ubrogepant,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0228), and 666 (placebo,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0339; ubrogepant,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0327) participants were triptan responders, triptan\u2010insufficient responders, and triptan\u2010na\u00efve, respectively. Response rates on co\u2010primary efficacy endpoints were higher for ubrogepant versus placebo across all groups. Treatment\u2010by\u2010subgroup interaction\n                      <jats:italic>p<\/jats:italic>\n                      values based on odds ratios for pain freedom (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.290) and absence of MBS (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.705) indicated no significant impact of historical triptan experience on ubrogepant efficacy. AE incidence for ubrogepant did not differ appreciably across historical triptan experience subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ubrogepant efficacy and tolerability did not differ for the acute treatment of migraine in participants classified as triptan responders, triptan\u2010insufficient responders, and triptan\u2010na\u00efve based on their historical experience with triptans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14089","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T07:17:15Z","timestamp":1616397435000},"page":"422-429","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis"],"prefix":"10.1111","volume":"61","author":[{"given":"Andrew M.","family":"Blumenfeld","sequence":"first","affiliation":[{"name":"The Neurology Center Headache Center of Southern California Carlsbad CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[{"name":"NIHR\u2010Wellcome Trust King's Clinical Research Facility King's College London UK"},{"name":"University of California Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic Phoenix AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-2846","authenticated-orcid":false,"given":"Susan","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Department of Headache Orange County Migraine and Headache Center Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Finnegan","sequence":"additional","affiliation":[{"name":"AbbVie Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"AbbVie Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Szegedi","sequence":"additional","affiliation":[{"name":"AbbVie Madison NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00752.x"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12154"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13588"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04078.x"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.03.008"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30146-2"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1026325"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"issue":"1","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1124\/jpet.119.261065","article-title":"Characterization of ubrogepant: a potent and selective antagonist of the human calcitonin gene\u2010related peptide receptor","volume":"373","author":"Moore E","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(00)00010-1"},{"issue":"1","key":"e_1_2_12_20_1","article-title":"Ubrogepant is effective for the acute treatment of migraine in patients for whom triptans are ineffective","volume":"59","author":"Blumenfeld AM","year":"2019","journal-title":"Headache"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419835459"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14114"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13073"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01790.x"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419889350"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.12.020"},{"issue":"4","key":"e_1_2_12_27_1","first-page":"368","article-title":"Health care resource utilization following initiation of a triptan: a retrospective claims analysis","volume":"20","author":"Messali A","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410383058"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14089","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14089","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:51:27Z","timestamp":1762084287000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/head.14089"],"URL":"https:\/\/doi.org\/10.1111\/head.14089","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"2020-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}